Pharvaris (PHVS) News Today $14.62 -0.33 (-2.21%) Closing price 04:00 PM EasternExtended Trading$14.64 +0.02 (+0.10%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Pharvaris (NASDAQ:PHVS) Stock Price Down 4.3% - What's Next?Pharvaris (NASDAQ:PHVS) Trading Down 4.3% - What's Next?April 3 at 12:59 PM | marketbeat.comPharvaris (PHVS) Projected to Post Earnings on WednesdayPharvaris (NASDAQ:PHVS) will be releasing earnings before the market opens on Wednesday, April 9, Financial Modeling Prep reports.April 3 at 1:21 AM | marketbeat.comPharvaris says EC grants orphan designation to deucrictibantApril 2 at 4:35 PM | markets.businessinsider.comPharvaris (PHVS) to Release Quarterly Earnings on WednesdayApril 2 at 1:23 AM | americanbankingnews.comPharvaris Announces Orphan Designation Granted to Deucrictibant by the European CommissionApril 1 at 7:02 AM | globenewswire.comPharvaris (NASDAQ:PHVS) Trading Up 6% - Still a Buy?Pharvaris (NASDAQ:PHVS) Trading 6% Higher - Here's What HappenedMarch 28, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Trading Up 5.5% - Should You Buy?Pharvaris (NASDAQ:PHVS) Shares Up 5.5% - Still a Buy?March 22, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Stock Price Down 3.2% - Time to Sell?Pharvaris (NASDAQ:PHVS) Trading Down 3.2% - Should You Sell?March 20, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Short Interest Up 24.7% in FebruaryPharvaris (NASDAQ:PHVS - Get Free Report) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 487,300 shares, a growth of 24.7% from the February 13th total of 390,900 shares. Based on an average trading volume of 55,500 shares, the days-to-cover ratio is currently 8.8 days. Approximately 2.8% of the company's stock are short sold.March 18, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Gap Down - Should You Sell?Pharvaris (NASDAQ:PHVS) Shares Gap Down - Here's What HappenedMarch 18, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Trading 4.3% Higher - Still a Buy?Pharvaris (NASDAQ:PHVS) Trading 4.3% Higher - Here's What HappenedMarch 14, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Gap Down - What's Next?Pharvaris (NASDAQ:PHVS) Shares Gap Down - Here's What HappenedMarch 12, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Gap Up - Time to Buy?Pharvaris (NASDAQ:PHVS) Shares Gap Up - Should You Buy?March 11, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Short Interest UpdatePharvaris (NASDAQ:PHVS - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 390,900 shares, a growth of 25.7% from the January 31st total of 311,100 shares. Approximately 2.3% of the company's shares are short sold. Based on an average daily volume of 64,900 shares, the short-interest ratio is currently 6.0 days.March 6, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Trading Down 5.7% - Here's WhyPharvaris (NASDAQ:PHVS) Shares Down 5.7% - Should You Sell?March 6, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Sets New 1-Year Low - Time to Sell?Pharvaris (NASDAQ:PHVS) Sets New 52-Week Low - Here's WhyMarch 6, 2025 | marketbeat.comPharvaris reports safety and efficacy data of deucrictibantMarch 3, 2025 | markets.businessinsider.comPharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint CongressMarch 3, 2025 | globenewswire.comPharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025March 3, 2025 | globenewswire.comPharvaris (NASDAQ:PHVS) Hits New 12-Month Low - Should You Sell?Pharvaris (NASDAQ:PHVS) Sets New 1-Year Low - Time to Sell?February 27, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Sees Large Volume Increase - Still a Buy?Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Should You Buy?February 24, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Sees Strong Trading Volume - What's Next?Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - What's Next?February 12, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Time to Buy?Pharvaris (NASDAQ:PHVS) Sees Large Volume Increase - Here's WhyFebruary 6, 2025 | marketbeat.comPharvaris price target raised to $55 from $46 at JMP SecuritiesJanuary 31, 2025 | markets.businessinsider.comJMP Securities Issues Positive Forecast for Pharvaris (NASDAQ:PHVS) Stock PriceJMP Securities lifted their price target on Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research note on Friday.January 31, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Gap Down - Here's What HappenedPharvaris (NASDAQ:PHVS) Shares Gap Down - What's Next?January 28, 2025 | marketbeat.comPharvaris FY2026 EPS Estimate Reduced by Leerink PartnrsPharvaris (NASDAQ:PHVS - Free Report) - Investment analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for Pharvaris in a report released on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($2.87) per share forJanuary 22, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Up 5.3% - Here's WhyPharvaris (NASDAQ:PHVS) Stock Price Up 5.3% - Here's WhyJanuary 21, 2025 | marketbeat.comBank of America Securities Sticks to Their Sell Rating for Pharvaris (PHVS)January 16, 2025 | markets.businessinsider.comPharvaris Positioned for Growth: Strategic Focus on Deucrictibant and Financial Stability Drive Buy RatingJanuary 15, 2025 | markets.businessinsider.comPharvaris (NASDAQ:PHVS) Shares Down 11.7% - Here's What HappenedPharvaris (NASDAQ:PHVS) Shares Down 11.7% - What's Next?January 13, 2025 | marketbeat.comPharvaris N.V.: Pharvaris Outlines 2025 Strategic PrioritiesJanuary 13, 2025 | finanznachrichten.dePharvaris Outlines 2025 Strategic PrioritiesJanuary 13, 2025 | globenewswire.comJane Street Group LLC Makes New Investment in Pharvaris (NASDAQ:PHVS)Jane Street Group LLC purchased a new position in Pharvaris (NASDAQ:PHVS - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 28,418 shares of the company's stock, valued at approximately $526,000. Jane StJanuary 6, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Sees Large Volume Increase - Here's What HappenedPharvaris (NASDAQ:PHVS) Sees Strong Trading Volume - Time to Buy?January 3, 2025 | marketbeat.comState Street Corp Purchases New Shares in Pharvaris (NASDAQ:PHVS)State Street Corp acquired a new position in Pharvaris (NASDAQ:PHVS - Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 53,980 shares of the company's stock, valued at approximateJanuary 3, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Trading Down 3.5% - Here's WhyPharvaris (NASDAQ:PHVS) Shares Down 3.5% - Time to Sell?December 31, 2024 | marketbeat.comPharvaris: Despite 30% Decline, Still Fair At BestDecember 29, 2024 | seekingalpha.comPharvaris (NASDAQ:PHVS) Sees Significant Drop in Short InterestPharvaris (NASDAQ:PHVS - Get Free Report) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totalling 152,100 shares, a drop of 24.8% from the November 30th total of 202,200 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average trading volume of 85,200 shares, the short-interest ratio is presently 1.8 days.December 28, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $906,000 in Pharvaris (NASDAQ:PHVS)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Pharvaris (NASDAQ:PHVS - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 48,896 shares of the company's stock,December 20, 2024 | marketbeat.comPharvaris price target lowered to $46 from $50 at JMP SecuritiesDecember 6, 2024 | markets.businessinsider.comPharvaris Reports Q3 2024 Progress and FinancialsNovember 25, 2024 | tipranks.comOppenheimer Remains a Buy on Pharvaris (PHVS)November 15, 2024 | markets.businessinsider.comPharvaris Advances in HAE Treatment with Strong FinancialsNovember 14, 2024 | markets.businessinsider.comPharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business UpdatesNovember 13, 2024 | globenewswire.comPharvaris to Participate in the Guggenheim Healthcare Innovation ConferenceNovember 12, 2024 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Waters (WAT), Pharvaris (PHVS) and Tandem Diabetes Care (TNDM)November 12, 2024 | markets.businessinsider.comPharvaris (NASDAQ:PHVS) Stock Quotes, Forecast and News SummaryOctober 29, 2024 | benzinga.comPharvaris’s Promising Developments in HAE Treatment Drive Buy RatingOctober 26, 2024 | markets.businessinsider.comPharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific MeetingOctober 24, 2024 | markets.businessinsider.com Remove Ads Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address PHVS Media Mentions By Week PHVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHVS News Sentiment▼0.060.60▲Average Medical News Sentiment PHVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHVS Articles This Week▼61▲PHVS Articles Average Week Remove Ads Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Akero Therapeutics News Crinetics Pharmaceuticals News Scholar Rock News Protagonist Therapeutics News Catalyst Pharmaceuticals News Alvotech News Merus News Immunovant News Metsera News MorphoSys News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHVS) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHVS Stock Free PHVS Stock Alerts